Total product sales -- $7.3 billion in fiscal Q3 2025, up 4% sequentially from Q2 2025, with growth driven by the HIV ...

Gross margin for 2025 was 31.8% (non-GAAP), up from 28.8% in 2024, at the upper end of the company’s targeted 27%-32% range ...